Figures & data
Table 1. Formulation design.
Figure 2. Scanning electron micrographs showing the particle morphology of zanamivir spray-drying powders at various formulations. (a) The powders prepared with zanamivir, Batch 1; (b) the powders prepared with zanamivir/mannitol (1/4), Batch 2; (c) the powders prepared with zanamivir/mannitol/leucine (1/3/1), Batch 3; (d) the powders prepared with zanamivir/mannitol/leucine (1/2/2), Batch 4; (e) the powders prepared with zanamivir/mannitol/leucine (1/1/3), Batch 5.
![Figure 2. Scanning electron micrographs showing the particle morphology of zanamivir spray-drying powders at various formulations. (a) The powders prepared with zanamivir, Batch 1; (b) the powders prepared with zanamivir/mannitol (1/4), Batch 2; (c) the powders prepared with zanamivir/mannitol/leucine (1/3/1), Batch 3; (d) the powders prepared with zanamivir/mannitol/leucine (1/2/2), Batch 4; (e) the powders prepared with zanamivir/mannitol/leucine (1/1/3), Batch 5.](/cms/asset/3178f5e4-f954-4f40-a00e-971e09800219/idrd_a_883113_f0002_b.jpg)
Table 2. Characteristics of zanamivir spray-drying powders (n = 3).
Figure 3. Moisture adsorption profile of zanamivir spray-drying powders at 45–85% relative humidity at 25 °C.
![Figure 3. Moisture adsorption profile of zanamivir spray-drying powders at 45–85% relative humidity at 25 °C.](/cms/asset/2fb0fe7d-1da7-4cc5-b12f-1b2e4a7a93b8/idrd_a_883113_f0003_b.jpg)
Table 3. Spray-drying variables and characteristics (Batch 5, zanamivir/mannitol/leucine, 1/1/3, n = 3).